ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Aprotinin showed high efficacy and safety in a prospective study of combination therapy for hospitalized patients with moderate to severe COVID-19 pneumonia.
Ivashchenko A. , Svistunov A. , Khorobryh T. , Loginov V. , Karapetian R. , Mishchenko N. , Poyarkov S. , Topr M. , Volgin M. , Yakubova E. , Ivachtchenko A. 2020. Aprotinin ‐ a new multi-target drug candidate or "magic shotgun" for the therapy of COVID‐19. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111821
1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/ bda7594740fd40299423467b48e9ecf6/.
2. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020, 107512. doi:10.1016/j.pharmthera.2020.107512.
3. Du Y-X, Chen X-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 2020, 108(2), 188. doi:10.1002/cpt.1844.
4. Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID‐19: What's next? Br. J. Pharmacol. 2020, 10.1111/bph.15072. doi: 10.1111/bph.15072.
5. Ivashchenko AA, Dmitriev KA, Vostokova NV et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin. Infect. Dis. 2020 Aug 9: ciaa1176, https://doi.org/10.1093/cid/ciaa1176.
6. Sisay M. Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19. Front Pharmacol. 2020, 11, 791. doi:10.3389/fphar.2020.00791.
7. Minister of Health of the Russian Federation. Interim guidelines prevention, diagnostics and treatment of new coronavirus infection (2019-nCoV) Version 7 (2020.06.03) (Russian language). https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/ 584/original/03062020_%D0%9CR_COVID-19_v7.pdf .
8. Remdesivir FDA Approval Status. Reviewed by Stewart J, B Pharm. 2020, https://www.drugs.com/history/remdesivir.html.
9. Gallagher GM. Remdesivir Submitted to FDA for US Approval. Contagion Live. 2020. https://www.contagionlive.com/news/remdesivir-submitted-fda-us-approval.
10. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19—preliminary report. N. Engl. J. Med. 2020. doi:10.1056/NEJMoa2007764.
11. Spinner CD, Gottlieb RL, Criner GF. et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020, e2016349. doi: 10.1001/jama.2020.16349.
12. Bloom J. Remdesivir Disappoints. Again. ACSH 2020. https://www.acsh.org/news/2020/08/24/remdesivir-disappoints-again-14982.
13. Chen W, Zheng KI, Liu S, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann. Clin. Microbiol. Antimicrob. 2020, 19, Article number: 18. https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-020-00362-2.
14. Zheng K I, Feng G, Liu W-Y, et al. Extrapulmonary complications of COVID‐19: A multisystem disease? J. Med. Virol. 2020, 10.1002/jmv.26294, doi: 10.1002/jmv.26294.
15. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/angiotensin‐(1‐7)/MAS axis of the renin‐angiotensin system: focus on angiotensin‐(1‐7). Physiol. Rev. 2018, 98(1), 505‐553. https://journals.physiology.org/doi/pdf/10.1152/physrev.00023.2016.
16. Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J. Pathol. 2003, 200(3), 282‐289.
17. Wang G, Wu C, Zhang O, et al. C-Reactive Protein Level May Predict the Risk of COVID19 Aggravation. OFID 2020, 7(5), ofaa153, https://doi.org/10.1093/ofid/ofaa153.
18. Fibrin/Fibrinogen Degradation Products and D-Dimers. MediaLab 2020, https://www.labce.com/spg131606_fibrinfibrinogen_degradation_products_and_d_dimers.aspx.
19. Righini M, Perrier A, De Moerloose P, et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. J. Thromb. Haemost. 2008, 6, 1059-1071. doi: 10.1111/j.1538-7836.2008.02981x
20. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020. doi: 10.1111/jth.14830.
21. Hayıroğlu MI, Çınar T, Tekkeşin AI. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. Rev. Assoc. Med. Bras. 2020, 66(6). https://doi.org/10.1590/1806-9282.66.6.842.
22. Thomas L. D-dimer-A-sensitive-novel-biomarker-of-COVID-19-mortality. News Medical 2020. https://www.news-medical.net/news/20200907/D-dimer-A-sensitive-novel-biomarker-of-COVID-19-mortality.aspx.
23. Garcia-Olivé I, Sintes H, Radua J, et al. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir. Med. 2020, 169, 106023. https://www.sciencedirect.com/science/article/pii/S0954611120301633.
24. Zhou, T. Yu, R. Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395 (10229), 1054-1062. 10.1016/S0140-6736(20)30566-3.
25. Danzi GB, Loffi M, Galeazzi G, et al. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020, 41(19), 1858. doi: 10.1093/eurheartj/ehaa254.
26. Cui S, Chen S, Li X, et al. Wang. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18(6), 1421-1424. doi: 10.1111/jth.14830.
27. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020, 191, 145-147. doi: 0.1016/j.thromres.2020.04.13
28. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18: 844-847.
29. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science, 2020, 368 (6490), 473-474.
30. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirusspike protein. J. Clin. Pathol. 2020. pii: jclinpath-2020-206658. doi: 10.1136/jclinpath-2020-206658 [Epub ahead of print].
31. Scheule AM, Beierlein W, Wendel HP, et al. Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. J. Thorac. Cardiovasc. Surg. 1999, 118(2), 348-353.
32. Ascenzi P, Bocedi A, Bolognesi M. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr. Protein Pept. Sci. 2003, 4(3), 231–251.
33. Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am. J. Health. Syst. Pharm. 2005, 62(18, S4), S9–14.
34. Solun B, Shoenfeld Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med. Drug. Discov. 2020, 100052. doi: 10.1016/j.medidd.2020.100052
35. Bojkova D, VcGreig JT, McLaughlin K-M. et al. SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug 2 sensitivity profiles. BioRxiv 2020, preprint doi: https://doi.org/10.1101/2020.04.03.024257.
36. Bestle D, Heindl VR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets. BioRxiv 2020, preprint doi: https://doi.org/10.1101/2020.04.15.042085. https://www.biorxiv.org/content/10.1101/2020.04.15. 042085v1.full.pdf.
37. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020, 181(2), 271-280.e8. doi:10.1016/j.cell.2020.02.052.
38. Cancer's next magic bullet may be magic shotgun. Science News. University of California - San Francisco 2012/. https://www.sciencedaily.com/releases/2012/06/ 120615141716.htm.
